79 related articles for article (PubMed ID: 24910022)
1. Use of imatinib in a patient with cutaneous vasculopathy in the context of von Recklinghausen disease/neurofibromatosis.
Khelifa I; Saurat JH; Prins C
Br J Dermatol; 2015 Jan; 172(1):253-6. PubMed ID: 24910022
[TBL] [Abstract][Full Text] [Related]
2. [Gastrointestinal stromal tumors in neurofibromatosis type 1].
Bajor J
Orv Hetil; 2009 Jan; 150(4):149-53. PubMed ID: 19144598
[TBL] [Abstract][Full Text] [Related]
3. Treatment for plexiform neurofibromas in patients with NF1.
Ardern-Holmes SL; North KN
Lancet Oncol; 2012 Dec; 13(12):1175-6. PubMed ID: 23099008
[No Abstract] [Full Text] [Related]
4. Experimental therapy for neurofibromatosis I shows promise: cancer drug shrinks some plexiform neuromas.
Am J Med Genet A; 2013 Feb; 161A(2):viii-ix. PubMed ID: 23348988
[No Abstract] [Full Text] [Related]
5. Vasculopathy in von Recklinghausen's neurofibromatosis--a diagnostic quandary.
Obermoser G; Zelger BG; Millonig G; Sepp N; Vogel W; Zelger B
J Am Acad Dermatol; 2004 May; 50(5 Suppl):S107-9. PubMed ID: 15097942
[TBL] [Abstract][Full Text] [Related]
6. Nf1+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway.
Lasater EA; Bessler WK; Mead LE; Horn WE; Clapp DW; Conway SJ; Ingram DA; Li F
Hum Mol Genet; 2008 Aug; 17(15):2336-44. PubMed ID: 18442999
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous vasculopathy manifested as skin ulcers in neurofibromatosis.
García-Gil MF; Lorda Espes M; Gracia-Cazaña T; Martínez García A; Ramirez-Lluch M; Monte Serrano J; Cruellas Lapeña M; Ara-Martín M
Int J Dermatol; 2020 May; 59(5):e142-e144. PubMed ID: 31984483
[No Abstract] [Full Text] [Related]
8. KIT mutations in a series of melanomas and their impact on treatment with imatinib.
Botella-Estrada R; Soriano V; Rubio L; Nagore E
Actas Dermosifiliogr; 2012 Nov; 103(9):838-40. PubMed ID: 22795573
[No Abstract] [Full Text] [Related]
9. Gastrointestinal stromal tumour.
Joensuu H; Hohenberger P; Corless CL
Lancet; 2013 Sep; 382(9896):973-83. PubMed ID: 23623056
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
[TBL] [Abstract][Full Text] [Related]
11. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.
Eskazan AE; Ayer M; Kantarcioglu B; Arica D; Demirel N; Aydin D; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Br J Haematol; 2014 Oct; 167(1):139-41. PubMed ID: 24815307
[No Abstract] [Full Text] [Related]
12. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.
Angelini S; Pantaleo MA; Ravegnini G; Zenesini C; Cavrini G; Nannini M; Fumagalli E; Palassini E; Saponara M; Di Battista M; Casali PG; Hrelia P; Cantelli-Forti G; Biasco G
Pharmacol Res; 2013 Feb; 68(1):1-6. PubMed ID: 23127916
[TBL] [Abstract][Full Text] [Related]
13. Inimitable Imatinib: the range of targeted tumours expands to include T-cell lymphoma.
Turner SD
Leukemia; 2013 Apr; 27(4):759. PubMed ID: 23575607
[No Abstract] [Full Text] [Related]
14. Successful treatment of unresectable dermatofibrosarcoma protuberans on finger with imatinib mesylate and Mohs microsurgery.
Jeon IK; Kim JH; Kim SE; Kim SC; Roh MR
J Dermatol; 2013 Apr; 40(4):288-9. PubMed ID: 23293988
[No Abstract] [Full Text] [Related]
15. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
[TBL] [Abstract][Full Text] [Related]
16. Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib.
Vij M; Patra S; Rela M
Indian J Pathol Microbiol; 2013; 56(3):291-3. PubMed ID: 24152514
[TBL] [Abstract][Full Text] [Related]
17. Clinical remission of Merkel cell carcinoma after treatment with imatinib.
Loader DE; Feldmann R; Baumgartner M; Breier F; Schrama D; Becker JC; Steiner A
J Am Acad Dermatol; 2013 Oct; 69(4):e181-3. PubMed ID: 24034390
[No Abstract] [Full Text] [Related]
18. Management of gastrointestinal stromal tumor: the imatinib era and beyond.
Parikh PM; Gupta S
Indian J Cancer; 2013; 50(1):31-40. PubMed ID: 23713042
[TBL] [Abstract][Full Text] [Related]
19. Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST.
Gasparotto D; Miolo G; Torrisi E; Canzonieri V; Bertola G; Libra M; Marzotto A; Maestro R; Buonadonna A
Int J Colorectal Dis; 2014 May; 29(5):639-40. PubMed ID: 24525699
[No Abstract] [Full Text] [Related]
20. Imatinib-induced amelioration of neurologic deficits in a rare case of simultaneous association of missed multiple sclerosis and chronic myeloblastic leukemia.
Siroos B; Harirchian MH; Abolfazli R
Mult Scler; 2013 Aug; 19(9):1238-9. PubMed ID: 23339135
[No Abstract] [Full Text] [Related]
[Next] [New Search]
